AlterDiag
AlterDiag is a French diagnostics startup (founded 2024) focused on research, development and commercialization of rapid lateral flow immunochromatographic diagnostic tests. The company concentrates on integrating single-domain and single-chain antibody reagents into point-of-care assays, coordinating assay characterization with diagnostic core facilities, and managing regulatory registrations and industrialization for market deployment.
Industries
Nr. of Employees
small (1-50)
AlterDiag
Clermont-Ferrand, Auvergne-Rhône-Alpes, France
Products
Sourced lateral flow diagnostic portfolio
A portfolio of third-party lateral flow tests that have been evaluated by the company's R&D and regulatory teams for distribution.
In-development lateral flow assays using single-domain antibodies
Proprietary lateral flow immunoassays in development that integrate single-domain antibody reagents to improve performance for pathogens of interest.
Sourced lateral flow diagnostic portfolio
A portfolio of third-party lateral flow tests that have been evaluated by the company's R&D and regulatory teams for distribution.
In-development lateral flow assays using single-domain antibodies
Proprietary lateral flow immunoassays in development that integrate single-domain antibody reagents to improve performance for pathogens of interest.
Services
Research and development of lateral flow immunochromatographic assays incorporating engineered antibody reagents.
Analytical assessment and selection of third-party lateral flow tests for distribution based on internal quality criteria.
Regulatory registration, compliance preparation, and commercialization planning for in vitro diagnostic devices.
Research and development of lateral flow immunochromatographic assays incorporating engineered antibody reagents.
Analytical assessment and selection of third-party lateral flow tests for distribution based on internal quality criteria.
Regulatory registration, compliance preparation, and commercialization planning for in vitro diagnostic devices.
Expertise Areas
- Rapid diagnostic test development
- Lateral flow immunoassays (LFIA)
- Single-domain antibody reagent development
- Assay characterization and performance evaluation
Key Technologies
- Lateral flow immunoassays (immunochromatography)
- Single-domain antibodies (VHH)
- Single-chain variable fragments (scFv)
- Assay characterization and optimization
News & Updates
Announcement of a €2M seed funding round to support development of rapid diagnostic tests and expansion of R&D and regulatory teams.
Announcement of a long-term strategic partnership with a diagnostic development core facility to co-develop single-domain antibody-based lateral flow tests and coordinate R&D and industrialization responsibilities.
Raised €2 million in seed funding to develop rapid diagnostic tests.
Signed a long-term strategic partnership with a diagnostic test innovation and development core facility to co-develop next-generation lateral flow diagnostics.
Announcement of a €2M seed funding round to support development of rapid diagnostic tests and expansion of R&D and regulatory teams.
Announcement of a long-term strategic partnership with a diagnostic development core facility to co-develop single-domain antibody-based lateral flow tests and coordinate R&D and industrialization responsibilities.
Raised €2 million in seed funding to develop rapid diagnostic tests.
Signed a long-term strategic partnership with a diagnostic test innovation and development core facility to co-develop next-generation lateral flow diagnostics.